BIOCRYST PHARMACEUTICALS INC (BCRX) › Net IncomeBIOCRYST PHARMACEUTICALS INC (BCRX) — Net IncomeAnnual figures by period end, from SEC filings.2009-12-31: -$13.45M2010-12-31: -$33.85M2011-12-31: -$56.95M2012-12-31: -$39.08M2013-12-31: -$30.11M2014-12-31: -$45.19M2015-12-31: -$43.02M2016-12-31: -$55.14M2017-12-31: -$65.78M2018-12-31: -$101.25M2019-12-31: -$108.90M2020-12-31: -$182.81M2021-12-31: -$184.06M2022-12-31: -$247.12M2023-12-31: -$226.54M2024-12-31: -$88.88M2025-12-31: $263.86M$263.86M2009-12-31Net Income (USD)2025-12-31Period endedNet IncomeChange YoYSource filing2025-12-31$263.86M—2026-02-26From 2025-01-012024-12-31-$88.88M—2026-02-26From 2024-01-012023-12-31-$226.54M—2026-02-26From 2023-01-012022-12-31-$247.12M—2025-02-25From 2022-01-012021-12-31-$184.06M—2024-02-27From 2021-01-012020-12-31-$182.81M—2023-02-27From 2020-01-012019-12-31-$108.90M—2022-02-28From 2019-01-012018-12-31-$101.25M—2021-03-01From 2018-01-012017-12-31-$65.78M—2020-03-13From 2017-01-012016-12-31-$55.14M—2019-03-14From 2016-01-012015-12-31-$43.02M—2018-03-12From 2015-01-012014-12-31-$45.19M—2017-02-27From 2014-01-012013-12-31-$30.11M—2016-02-26From 2013-01-012012-12-31-$39.08M—2015-03-02From 2012-01-012011-12-31-$56.95M—2014-03-10From 2011-01-012010-12-31-$33.85M—2013-03-11From 2010-01-012009-12-31-$13.45M—2012-03-06From 2009-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)